medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2013, Number 2

<< Back Next >>

Arch Neurocien 2013; 18 (2)

Epilepsy during pregnancy

Bistre-Tajfed M, Vázquez-Alfaro R

Language: Spanish
References: 72
Page: 82-91
PDF size: 132.95 Kb.


ABSTRACT

During pregnancy, epilepsy is considered the most frequent neurological disorder affecting up to 1% of women of childbearing age. Control of disease remains a factor that contributes significantly to maternal and perinatal morbidity is necessary to proper management from initial preconception through lactation to reduce these risks, from choosing a contraceptive method that does not reduce its effectiveness by the disease or its treatment, changing the therapeutic regimen before pregnancy to reduce the risk of malformations defects or disruptions in cognitive development. Other important considerations include prenatal diagnosis of fetal malformations, the use of folic acid and vitamin K, and the board of nursing.


REFERENCES

  1. Vélez L C. Epidemiología de la epilepsia en niños. Epilepsia, progresos en el tratamiento. México: Centro de Comunicación Ciba. 1983.

  2. Figueroa AS. Aspectos psicosociales de la epilepsia. Arch Neurocien 2004;9(3):135-42.

  3. WHO, Factsheet 999, epilepsy, www.who.int/mediacentre/ factsheets/fs999/en/index.html revisada el 1° de junio del 2010.

  4. Kaaja E, Kaaja R. Major malformations in the offspring of women with epilepsy. Neurol 2003; 60(4):375-579.

  5. Lorenzato R, Cavalli R, Duarte G, Sakamoto A, Mauad F, Nogueira A. Epilepsy and pregnancy: evolution and fetal outcome. RGBO 2002;24(8):521-6.

  6. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester Minnesota 1940-1980. Epilepsia 1991;32:429- 45.

  7. INEGI. Estadísticas a propósito del día internacional de la mujer, http://www.inegi.org.mx/inegi/contenidos/espanol/ prensa/contenidos/estadisticas/2011/mujer11.asp?s= inegi&c=2784&ep=53. Revisada en 03 de abril del 2102

  8. Artama M, Isojärvi JIT, Raitanen J. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004;159:1057-63.

  9. Schachter SC, Schomer DL. The comprehensive evaluation and treatment of epilepsy.San Diego, CA: AcademicPress; 1997:207-32.

  10. Walker SP, Permezel M, BerkovicSF.The management of epilepsy in pregnancy. BJOG 2009;116:758-67.

  11. Isojarvi J. Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. Seizure 2008;17: 111-9.

  12. Artama M, Isojarvi JIT, Auvinen A. Antiepileptic drug use and birth rate in patients with epilepsy - a population-based cohort study in Finland. Hum Reprod 2006;21:2290-5.

  13. Nájera DC, Gutiérrez AM. Epilepsia en la mujer, por qué es especial. Acta Neurol Colomb 2005;21:7-11.

  14. Schwenkhagen AM, Stodieck SRG. Which contraception for women with epilepsy. Seizure 2008;17(2):145-50.

  15. O’Brien MD, Guillebaud J. Contraception for woman with epilepsy. Epilepsia 2006;57(9):1419-22.

  16. Guberman A. Hormonal contraception and epilepsy. Neurol 1999;1:538-40.

  17. Serrano PJ, Casado JL, Mercadé JM, Altuzara A. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: Tratamiento antiepiléptico en situaciones especiales. Rev Neurol 2005;40(11):683-95.

  18. De la Peña P. Anticoncepción y epilepsia. En: Forcades MI. Epilepsia y mujer. 2° ed. Madrid: Harcourt;2002.

  19. Herzog AG, Farina EL, Blum AS. Serum valproate levels with oral contraceptive use. Epilepsia 2005;46(6):970-1.

  20. Crawford P. Best practice guidelines for the managment of women with epilepsy. Epilepsia 2005;46(9):117-24.

  21. Vajda FJE, Hitchcock A, Graham J, O’Brien T, Lander C, Eadie M. Seizure control in antiepileptic drug-treated pregnancy. Epilepsia 2008;49:172-5.

  22. Serrano PJ, Casado JL, Mercadé JM, Altuzara A. Guía terapéutica en epilepsia de la sociedad Andaluza de Epilepsia 2005: Tratamiento antiepiléptico en situaciones especiales. Rev Neurol 2005;40(11):683-95.

  23. Anónimo. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurol 1998;51:944-8.

  24. Chadwick D. The discontinuation of AED therapy. In Pedley TA, Meldrum BS eds: Recent advances in Epilepsy. Edinburgh: Churchill Livingstone 1985:111-24.

  25. Kampman MT. Folate status in women of child-bearing age with epilepsy. Epilepsy Res 2007;75:52-6.

  26. Vajda FJE, Hitchcock A, Graham J. The australian register of antiepileptic drugs in pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007;47:468-74.

  27. The EURAP Study Group.Seizure controland treatment in pregnancy.Observations from the EURAP Epilepsy Pregnancy Registry. Neurology 2006;66:354-60.

  28. Schmidt D, Canger R. Change of seizure frequency in pregnant epileptic women. J Neurol Neurosurg Psychiatry 1983;46:751-5.

  29. Vajda FJE. Treatment options for pregnant women with epilepsy. Expert OpinPharpamcother 2008;9(11):1859-68.

  30. LaJoie J, Moshe SL. Effects of seizures and their treatment on fetal brain. Epilepsia 2004;45(8):48-52.

  31. Meador K. Neurodevelopmental outcomes of children born to mothers with epilepsy. Cleve Clin J Med 2004;71(2):38-41.

  32. Gutiérrez AM, Ruíz AM. La embarazada con epilepsia: recomendaciones para su evaluación y manejo. Acta Neurol Colomb 2005;21(1):66-72

  33. Harden CL, Meador KJ, Penell PB. Practice parameter update: Management issues for women with epilepsy – Focus on pregnancy: Teratogenesis and perinatal outcomes. Neurology 2009;73:133-41.

  34. Vélez A, Ortíz PA. Problemas de los hijos de madres con epilepsia. Acta Neurol Colomb 2005;21(1):73-81.

  35. Artama M, Auvinen A, Raudaskoski T, Isojar vi I, Isojarvi J. Antiepileptic drug use of women with epilepsy and congenital malformations in the offspring. Neurology 2005;64:1874-8.

  36. Samren EB, van Dujin CM, Kock S. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38(9):981-90.

  37. Jager-Roman E, Deichl A, Jacob S. Fetal growth major malformationsand minor abnormalities in infants born to woman receiving valproic acid. J Pediatr 1986;108:997-1004.

  38. Saiz-Díaz RA, Porta Etessam J, García Morales I. Epilepsia y embarazo. Neurología 2000;15:461.

  39. Martínez Ferri M. Malformaciones y lesiones fetales en las embarazadas epilépticas. En: ForcadesMI. Epilepsia y mujer. 2° ed. Madrid: Harcourt;2002.

  40. Lindhout D, Meinardi H, Meijer JWA. Antiepileptic drugs and teratogenesis in two consecutive cohor ts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992;42(5):94-110

  41. Keneko S, Otani T. Malinfants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992;42(5):68-74.

  42. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975;87:285-90.

  43. Colmes L, Har vey E, Coull B. The teratogenicity of anticonvulsant drugs. New England J Med 2001;344 (15):1132-8.

  44. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic anbnormalities and a review of the literature. Am J Med Genet 2001;98:168-75.

  45. Mølgaard-Nielsen D, Hviid A. Newer generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305 (19):1996-2002.

  46. Moore KL, Persaud TVN. Embriología clínica. 8 ed. Barcelona: ELSEVIER; 2008.

  47. Gaily E, Kantola-Sorsa E, Hiilesmaa V. Normal inteligence in children with prenatal exposure to carbamazepine. Neurology 2004;62(1):8-9.

  48. Banach R, Boskovic R. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010;33(1):73-9.

  49. Gaily E, Kantola-Sorsa E, Granström ML. Intelligence of children of epileptic mothers. J Pediatrics 1988;113:667- 84.

  50. Katz JM, Pacia S, Devinsky O. Current management of epilepsy and pregnancy: Fetal outcome, congenital malformations, and developmental delay. Epilepsy and Behavior 2001;2:119-23.

  51. Yerby MS. Management issues for women with epilepsy: neural tube defects and folic acid supplementation. Neurology 2003;61(2):S23-6.

  52. Pennel PB. Pregnancy in the women with epilepsy: maternal and fetal outcomes. Seminars in neurology 2002;22(3):299- 307.

  53. Pennel PB. Pregnancy in the women with epilepsy: maternal and fetal outcomes. Seminars in neurology 2002;22(3):299- 307.

  54. Pirie AM. Epilepsy in pregnancy. J R Coll Physicians Edinb 2005;35:236-8.

  55. http://www.who.int/mediacentre/factsheets/fs999/es/ Revisada en mayo 2012

  56. The EURAP Study Group.Seizure control and treatment in pregnancy. Neurology 2006;66:354-60.

  57. Bardy A. Epilepsy and pregnancy, a prospective study of 154 pregnancies in epileptic women. Helsinki, Finland: University of Helsinki, 1982.

  58. Betts T, Crawford P. Women and epilepsy. London, UK: Martin Dunitz, 1998;27-8.

  59. Sabers A. Complications during pregnancy and delivery. In: TomsonT, Gram L, Sillanpaa M, et al, eds. Epilepsy and pregnancy. Chichester, UK. Wrightson Biomedical Publishing Ltd 1997;105-11.

  60. Yerby MS. Contraception, pregnancy and lactation in women with epilepsy. BaillieresClinNeurol1996;5:887-908.

  61. Harden CL, Hopp J, Ting TY. Academy of Neurology and American Epilepsy SocietyTherapeutics and Technology Assessment Subcommittee of the American seizure frequency. Neurology 2009;73:126-32.

  62. Clarkson P, James A. Parenteral vitamin K: the effective prophylaxis against haemorrhagic disease for all newborn infants. N Z Med J1990;103:95-6.

  63. Harden CL, Pennell PB. Management issues for women with epilepsy-Focus onpregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding. Epilepsia 2009;50(5):1247-55.

  64. Ito S, Moretti M, Liau M, Koren G. Initiation and duration of breastfeeding in women receiving antiepileptic drugs. Am J Obstet Gynecol 1995;172:881-6.

  65. Fairgrieve SD, Jackson M, Jonas P. Population basedprospective study of the care of women with epilepsy inpregnancy. Br Med J 2000;321:674-5.

  66. Matheson I, Skjaeraasen J. Milk concentrations of flupenthixol, nortriptylineand zuclopenthixol and between breast differences in two patients. Eur J Pharmacol 1988;35:217- 20.

  67. Fleishaker JC, Desai N, McNamara PJ. Factors affecting the milk to plasma drug concentration ratio in lactating women: physical interactions with protein and fat. J Pharmacol Sci 1987;76:189-93.

  68. Liporace J, Kao A, D’Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav 2004;5:102-5.

  69. Chen L, Liu F, Yoshida S. Is breast-feeding of infants advisable for epileptic mothers taking antiepileptic drugs? Psychiatry and clinical neurosciences 2010;64(5):460-8.

  70. Sabers A. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure 2008;17:141-4.

  71. Eadie MJ. Antiepileptic drugs as human teratogens.Expert Opin.Drug Saf. 2008;7(2):195-209.

  72. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposure. Reprod Toxicol 2002;16(1):9-17.




2020     |     www.medigraphic.com